Petracci E, Pasini L, Urbini M, Felip E, Stella F, Davoli F, Salvi M, Beau-Faller M, Tebaldi M, Azzali I, Canale M, Solli P, Lai G, Amat R, Carbonell C, Falcoz PE, Martinez-Marti A, Pencreach E, Delmonte A, Crinò L, Ulivi P

J Exp Clin Cancer Res. 2024 08 22;43(1):241

Primary resistance to ALK inhibitors in -rearranged pleural metastatic lung adenocarcinoma: a case report.

Siblini L, Schott R, Trensz P, Pencreach E, Bender L

Transl Lung Cancer Res. 2023 11 30;12(11):2342-2346

Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer.

Nounsi A, Seitlinger J, Ponté C, Demiselle J, Idoux-Gillet Y, Pencreach E, Beau-Faller M, Lindner V, Balloul JM, Quemeneur E, Burckel H, Noël G, Olland A, Fioretti F, Falcoz PE, Benkirane-Jessel N, Hua G

Biomedicines. 2023 06 26;11(7):

Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.

Pabst L, Lopes S, Bertrand B, Creusot Q, Kotovskaya M, Pencreach E, Beau-Faller M, Mascaux C

Int J Mol Sci. 2023 04 20;24(8):

Acquired L718V/ co-mutation and discordant molecular pattern between plasmatic and cerebrospinal fluid in a bone and meningeal metastatic L858R+ non-small cell lung cancer: a case report.

Schultz É, Pencreach E, Rimelen V, Palama A, Holder É, Gantzer J, Bender L

Ann Transl Med. 2023 03 15;11(5):223

p16 Immunohistochemical Expression as a Surrogate Assessment of CDKN2A Alteration in Gliomas Leading to Prognostic Significances.

Geyer L, Wolf T, Chenard MP, Cebula H, Schott R, Noel G, Guerin E, Pencreach E, Reita D, Entz-Werlé N, Lhermitte B

Cancers (Basel). 2023 02 28;15(5):

All pineal tumors expressing germ cell tumor markers are not necessarily germ cell tumors: histopathological and molecular study of a midline primary intracranial sarcoma DICER1-mutant.

Wolf T, Coca AH, Weingertner N, Chenard MP, Meurgey A, Reita D, Pencreach E, Varlet P, Entz-Werlé N, Lhermitte B

Virchows Arch. 2022 10 28;:

The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response.

De Azevedo J, Mourtada J, Bour C, Devignot V, Schultz P, Borel C, Pencreach E, Mellitzer G, Gaiddon C, Jung AC

Cells. 2022 09 14;11(18):

Engineering Novel 3D Models to Recreate High-Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment.

Pierrevelcin M, Flacher V, Mueller CG, Vauchelles R, Guerin E, Lhermitte B, Pencreach E, Reisch A, Muller Q, Doumard L, Boufenghour W, Klymchenko AS, Foppolo S, Nazon C, Weingertner N, Martin S, Briandet C, Laithier V, Di Marco A, Bund L, Obrecht A, Villa P, Dontenwill M, Entz-Werlé N

Adv Healthc Mater. 2022 09 4;:e2200195

[Impact of NGS results on patient outcome with a multiform glioblastoma].

Rom M, Schott R, Pencreac'h E, Cébula H, Cox D, Bender L, Antoni D, Lhermitte B, Noel G

Cancer Radiother. 2022 06 14;:

Direct Targeting Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.

Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M

Cancers (Basel). 2022 Mar 4;14(5):

Molecular Mechanism of EGFR-TKI Resistance in -Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring.

Reita D, Pabst L, Pencreach E, Guérin E, Dano L, Rimelen V, Voegeli AC, Vallat L, Mascaux C, Beau-Faller M

Cancers (Basel). 2021 Sep 30;13(19):

SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.

Jannier S, Kemmel V, Sebastia Sancho C, Chammas A, Sabo AN, Pencreach E, Farace F, Chenard MP, Lhermitte B, Geoerger B, Aerts I, Frappaz D, Leblond P, André N, Ducassou S, Corradini N, Bertozzi AI, Guérin E, Vincent F, Velten M, Entz-Werle N

Cancers (Basel). 2020 Oct 20;12(10):

Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the Fren

Beau-Faller M, Pencreach E, Leduc C, Blons H, Merlio JP, Bringuier PP, de Fraipont F, Escande F, Lemoine A, Ouafik L, Denis M, Hofman P, Lacave R, Melaabi S, Langlais A, Missy P, Morin F, Moro-Sibilot D, Barlesi F, Cadranel J,

Lung Cancer. 2019 Nov 15;140:19-26

Constitutive or Induced HIF-2 Addiction is Involved in Resistance to Anti-EGFR Treatment and Radiation Therapy in HNSCC.

Coliat P, Ramolu L, Jégu J, Gaiddon C, Jung AC, Pencreach E

Cancers (Basel). 2019 Oct 21;11(10):

Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells.

Reita D, Bour C, Benbrika R, Groh A, Pencreach E, Guérin E, Guenot D

Cancers (Basel). 2019 Oct 17;11(10):

Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis.

Rimelen V, Ahle G, Pencreach E, Zinniger N, Debliquis A, Zalmaï L, Harzallah I, Hurstel R, Alamome I, Lamy F, Voirin J, Drénou B

Acta Neuropathol Commun. 2019 Mar 18;7(1):43

Dynamic evolution of clonal composition and neoantigen landscape in recurrent metastatic melanoma with a rare combination of driver mutations.

Davidson G, Coassolo S, Kieny A, Ennen M, Pencreach E, Malouf GG, Lipsker D, Davidson I

J. Invest. Dermatol.. 2019 Feb 15;:

Laminin α1 orchestrates VEGFA functions in the ecosystem of colorectal carcinoma.

Mammadova-Bach E, Rupp T, Spenlé C, Jivkov I, Shankaranarayanan P, Klein A, Pisarsky L, Méchine-Neuville A, Cremel G, Kedinger M, De Wever O, Ambartsumian N, Robine S, Pencreach E, Guenot D, Simon-Assmann P, Goetz JG, Orend G, Lefebvre O

Biol. Cell. 2018 Jun 15;:

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1α axis inhibition.

Nguyen A, Moussallieh FM, Mackay A, Cicek AE, Coca A, Chenard MP, Weingertner N, Lhermitte B, Letouzé E, Guérin E, Pencreach E, Jannier S, Guenot D, Namer IJ, Jones C, Entz-Werlé N

Oncotarget. 2017 Sep 22;8(42):71597-71617

Characterization of the transcriptional and metabolic responses of pediatric high grade gliomas to mTOR-HIF-1a axis inhibition.

Nguyen A, Moussallieh FM, Mackay A, Cicek AE, Coca A, Pierre Chenard M, Weingertner N, Lhermitte B, Letouzé E, Guérin E, Pencreach E, Jannier S, Guenot D, Jacques Namer I, Jones C, Entz-Werlé N

Oncotarget. 2017 Mar;:

Histone hypoacetylation contributes to CXCL12 downregulation in colon cancer : impact on tumor growth and cell migration.

Romain B, Benbrika-Nehmar R, Marisa L, Legrain M, Lobstein V, Oravecz A, Poidevin L, Bour C, Freund JN, Duluc I, Guenot D, Pencreach E

Oncotarget. 2017 Mar;:

Human Papillomavirus-related tumours of the oropharynx display a lower tumour hypoxia signature.

Hanns E, Job S, Coliat P, Wasylyk C, Ramolu L, Pencreach E, Suarez-Carmona M, Herfs M, Ledrappier S, Macabre C, Abecassis J, Wasylyk B, Jung AC

Oral Oncol. 2015 Jun 26. pii: S1368-8375(15)00237-7

Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer.

Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, Gaub MP, Pencreach E, Guenot D

Mol Cancer. 2014 Mar 14;13:58

Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2.

Derbal-Wolfrom L, Pencreach E, Saandi T, Aprahamian M, Martin E, Greferath R, Tufa E, Choquet P, Lehn JM, Nicolau C, Duluc I, Freund JN

Oncogene. 2013 Sep 5;32(36):4313-8

Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.

Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, Etienne-Grimaldi MC, Schiappa R, Guenot D, Ayadi M, Kirzin S, Chazal M, Flejou JF, Benchimol D, Berger A, Lagarde A, Pencreach E, Piard F, Elias D, Parc Y, Olschwang S, Milano G, Laurent-Puig P, Boige V

PLoS Med. 2013;10(5):e1001453

Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse.

Nguyen A, Lasthaus C, Guerin E, Marcellin L, Pencreach E, Gaub MP, Guenot D, Entz-Werle N

Cancers (Basel). 2013 Jun 4;5(2):662-75

Synthetic polyamines promote rapid lamellipodial growth by regulating actin dynamics.

Nedeva I, Koripelly G, Caballero D, Chieze L, Guichard B, Romain B, Pencreach E, Lehn JM, Carlier MF, Riveline D

Nat Commun. 2013;4:2165

In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1alpha target genes and decreases tumor angiogenesis.

Guerin E, Raffelsberger W, Pencreach E, Maier A, Neuville A, Schneider A, Bachellier P, Rohr S, Petitprez A, Poch O, Moras D, Oudet P, Larsen AK, Gaub MP, Guenot D

Mol Med. 2012 Feb 10;18(1):83-94

Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.

Pencreach E, Guerin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D

Clin Cancer Res. 2009 Feb 15;15(4):1297-307

Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes.

Weber JC, Meyer N, Pencreach E, Schneider A, Guerin E, Neuville A, Stemmer C, Brigand C, Bachellier P, Rohr S, Kedinger M, Meyer C, Guenot D, Oudet P, Jaeck D, Gaub MP

Int J Cancer. 2007 Feb 1;120(3):524-32.

Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability.

Guenot D, Guerin E, Aguillon-Romain S, Pencreach E, Schneider A, Neuville A, Chenard MP, Duluc I, Du Manoir S, Brigand C, Oudet P, Kedinger M, Gaub MP

J Pathol. 2006 Apr;208(5):643-52.